ReviewJournal of cellular and molecular medicine2018
Chemical, biochemical, preclinical and clinical studies of Ganoderma lucidum polysaccharide as an approved drug for treating myopathy and other diseases in China.
Review in Journal of cellular and molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- The dual role of Ganoderma lucidum polysaccharides in cancer treatment: Meridian tropism-based direct inhibition and immune-mediated modulation.Journal of the Chinese Medical Association : JCMA · 2026Review
- Review
- Bioactivity Research inBiology · 2026Review
- Article
- Review
- A review of the extraction technologies, structural characterization, chemical modification, and pharmacological effects of Ganoderma lucidum polysaccharides.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Impact of Hericium erinaceus and Ganoderma lucidum metabolites on AhR activation in neuronal HT-22 cells.Pharmacological reports : PR · 2025Article
- High-quality genome assembly and annotation of Porodaedalea mongolica and Porodaedalea schrenkiana provide insights into potential industrial and medical application.G3 (Bethesda, Md.) · 2025Article
- Mechanisms of action of fungal polysaccharides and their therapeutic effect.European journal of clinical nutrition · 2025Review
- Structure-function insights of natural Ganoderma polysaccharides: advances in biosynthesis and functional food applications.Natural products and bioprospecting · 2025Review
- Integrated Transcriptomic and Targeted Metabolomic Analysis Reveals the Key Genes Involved in Triterpenoid Biosynthesis ofJournal of fungi (Basel, Switzerland) · 2025Article
- Bioactivities and industrial standardization status ofHeliyon · 2024Review
- Study on Differences of Metabolites among DifferentJournal of fungi (Basel, Switzerland) · 2024Article
- Comparative Study on the Mechanism of Macrophage Activation Induced by Polysaccharides from Fresh and Dried Longan.Nutrients · 2024Article
- Polysaccharides from Chinese herbs as natural weapons against colorectal cancer.Bioscience reports · 2023Review
- The key technologies of Ganoderma lucidum liquid spawn preparation and scale expansion.World journal of microbiology & biotechnology · 2023Article
- Immunomodulatory function and anti-tumor mechanism of natural polysaccharides: A review.Frontiers in immunology · 2023Review
- Effects ofFrontiers in nutrition · 2023Article
- Corrigendum: Immunomodulatory function and anti-tumor mechanism of natural polysaccharides: a review.Frontiers in immunology · 2023Article
- A Review ofBiomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ganoderma lucidum is an edible medicinal mushroom known as "Lingzhi" in China and "Reishi or Manetake" in Japan. It is a highly prized vitality-enhancing herb for more than 2000 years. G. lucidum polysaccharide (GLPS) has been identified as one of the major bioactive components and developed into a drug named "Ji 731 Injection" in China since 1973. The large-scale production of the drug began in 1985 and approved by the Chinese FDA as "Polysaccharidum of G. lucidum Karst Injection" (Ling Bao Duo Tang Zhu She Ye) in 2000, which is applied intramuscularly. After more than forty years of clinical use, its efficacy, safety and long-term tolerability have been recognized by neurologists. It is one of a few non-hormonal drugs used for treating refractory myopathy. It is also used for combination therapy, which reduces the amount of glucocorticoid required for myopathy patient who is in remission. In addition, it reduces adverse reactions and improves the quality of life for cancer patients during chemotherapy. We found 81 qualified chemical, biochemical, preclinical and clinical studies of GLPS both in English and in Chinese spanning from 1973 to 2017 by searching CNKI (China National Knowledge Infrastructure), Wanfang database and PubMed. The molecular mechanisms underlying GLPS's antioxidant, anti-tumour, immune-modulatory, hypoglycaemic, hypolipidaemic and other activities are discussed. Both preclinical and clinical studies are either deliberated or indexed in the current article. We aimed at providing a molecular picture as well as a clinical basis to comprehend GLPS as one of few polysaccharide-based modern medicines with complicated chemical and pharmacological properties that prevent it from entering the world's market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.